- Free from Publisher AJM Rennings, P Smits, MW Stewart, CJ Tack - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a randomized, double-blind, placebo-controlled,
cross-over study in 18 obese, nondiabetic subjects with features of the
metabolic syndrome, we investigated the effects of a 12-week treatment with ... Cited by 21 - Related articles - BL Direct - All 8 versions
A Raji, MD Gerhard-Herman, JS Williams, … - Diabetic Medicine, 2006 - pt.wkhealth.com Results Asian Indians were insulin resistant compared with Causasians during the
baseline clamp (M = 25.6 ± 1.7 vs. 41.1 ± 2.2 µmol / kg per min, P < 0.0001)
and improved significantly after pioglitazone (to 33.9 ± 1.7 µmol / kg ... Cited by 3 - Related articles - BL Direct - All 5 versions
M Emoto, N Fukuda, Y Nakamori, A Taguchi, … - Diabetologia, 2006 - Springer Page 1. RESEARCH LETTER Plasma concentrations of vascular endothelial growth factor
are associated with peripheral oedema in patients treated ... Cited by 4 - Related articles - BL Direct - All 3 versions
- ►iupui.edu [PDF] C Nofziger, L Chen, MA Shane, CD Smith, KK … - Pflügers Archiv European Journal of Physiology, 2005 - Springer Abstract Selective agonists of peroxisome proliferator- activated receptor gamma
(PPARc) are anti-diabetic drugs that enhance cellular responsiveness to insulin.
However, in some patients, fluid retention, plasma vol- ume expansion, and ... Cited by 24 - Related articles - BL Direct - All 4 versions
- ►fasebj.org [PDF] KB Sotiropoulos, A Clermont, Y Yasuda, C … - The FASEB Journal, 2006 - FASEB In this study, we investigated the underlying mechanisms that cause the serious
adverse effects of PPAR agonists (rosiglitazone, RSG)—edema and wt gain—in
models of diabetes and insulin resistance with the following aims: 1. To ... Cited by 29 - Related articles - BL Direct - All 4 versions
[CITATION] PPARgamma activation improves cardiac energy metabolism in patients with type 2 diabetes …
T KAHARA, T TAKAMURA, T MISAKI, M … - Endocrine journal, 2005 - cat.inist.fr Pioglitazone is an insulin-sensitizer with a thiazolidinedione structure. It is
used to reduce hyperglycemia and is frequently prescribed to type 2 diabetic
patients. However, it causes edema as an adverse effect in some patients. ... Cited by 3 - Related articles - BL Direct - All 3 versions
[CITATION] Baseline B-type natriuretic peptide identifies patients with type 2 diabetes and class I/II heart …
GN Kalambokis, AA Tsatsoulis, EV Tsianos - American Journal of Kidney Diseases, 2004 - Elsevier The edematogenic properties of insulin have long been documented, although they
have been underestimated despite current trends toward intensive insulin
therapy. Insulin treatment has been associated with weight gain, mild or ... Cited by 27 - Related articles - BL Direct - All 8 versions
